




Pipeline



*Two phase 1 studies of CY6463 were completed in healthy young and old (>65 years of age) volunteers confirming targeted CNS exposure and activity. Status of programs as of July 28, 2022. Represents ongoing phase of development; does not correspond to the initiation or completion of a particular phase. CY6463 is the revised compound name for IW-6463. IW-6463 will be referenced in various existing articles, trial descriptions, etc.

